{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:18Z","timestamp":1787016978952,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135991"],"award-info":[{"award-number":["1135991"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1138442"],"award-info":[{"award-number":["1138442"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["296569"],"award-info":[{"award-number":["296569"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,2]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The POPPY II cohort is an Australian state-based cohort linking data for a population of individuals prescribed opioid medicines, constructed to allow a robust examination of the long-term patterns and outcomes of prescription opioid use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The cohort includes 3\u2009569\u2009433 adult New South Wales residents who initiated a subsidised prescription opioid medicine between 2003 and 2018, identified through pharmacy dispensing data (Australian Pharmaceutical Benefits Scheme) and linked to 10 national and state datasets and registries including rich sociodemographic and medical services data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>Of the 3.57\u2009million individuals included in the cohort, 52.7% were female and 1 in 4 people were aged \u226565\u2009years at the time of cohort entry. Approximately 6% had evidence of cancer in the year prior to cohort entry. In the 3\u2009months prior to cohort entry, 26.9% used a non-opioid analgesic and 20.5% used a psychotropic medicine. Overall, 1 in 5 individuals were initiated on a strong opioid (20.9%). The most commonly initiated opioid was paracetamol\/codeine (61.3%), followed by oxycodone (16.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>The POPPY II cohort will be updated periodically, both extending the follow-up duration of the existing cohort, and including new individuals initiating opioids. The POPPY II cohort will allow a range of aspects of opioid utilisation to be studied, including long-term trajectories of opioid use, development of a data-informed method to assess time-varying opioid exposure, and a range of outcomes including mortality, transition to opioid dependence, suicide and falls. The duration of the study period will allow examination of population-level impacts of changes to opioid monitoring and access, while the size of the cohort will also allow examination of important subpopulations such as people with cancer, musculoskeletal conditions or opioid use disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-068310","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T11:02:28Z","timestamp":1684321348000},"page":"e068310","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cohort profile: POPPY II \u2013 a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8470","authenticated-orcid":false,"given":"Natasa","family":"Gisev","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"School of Population Health, UNSW Sydney, Sydney, New South Wales, Australia"},{"name":"Menzies Centre for Health Policy, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Dobbins","sequence":"additional","affiliation":[{"name":"School of Population Health, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Buizen","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Murphy","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[{"name":"Menzies Centre for Health Policy, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blyth","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dunlop","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Drug and Alcohol Clinical Services, Hunter New England Local Health District, NSW Health, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larney","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Emergency Medicine and Centre de Recherche du Centre Hospitalier, de l'Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Currow","sequence":"additional","affiliation":[{"name":"Faculty of Science Medicine and Health, The University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P","family":"Mattick","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"2025120600444686000_13.5.e068310.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6"},{"key":"2025120600444686000_13.5.e068310.2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12937"},{"key":"2025120600444686000_13.5.e068310.3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bcp.13792","article-title":"Prevalence and incidence of prescription opioid analgesic use in Australia","volume":"85","author":"Lalic","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2025120600444686000_13.5.e068310.4","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12446"},{"key":"2025120600444686000_13.5.e068310.5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s40429-018-0227-6","article-title":"Current opioid access, use, and problems in Australasian jurisdictions","volume":"5","author":"Gisev","year":"2018","journal-title":"Curr Addict Rep"},{"key":"2025120600444686000_13.5.e068310.6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pds.3931","article-title":"The extent and correlates of community-based pharmaceutical opioid utilisation in Australia","volume":"25","author":"Degenhardt","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120600444686000_13.5.e068310.7","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2014.496.x"},{"key":"2025120600444686000_13.5.e068310.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00355-9"},{"key":"2025120600444686000_13.5.e068310.9","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"The Lancet"},{"key":"2025120600444686000_13.5.e068310.10","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.6.627"},{"key":"2025120600444686000_13.5.e068310.11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Int Medicine"},{"key":"2025120600444686000_13.5.e068310.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2011.00291.x"},{"key":"2025120600444686000_13.5.e068310.13","unstructured":"Institute of Medicine . Relieving pain in America: a blueprint for transforming prevention, care, education and research. Washington DC: The National Academies Press, 2011."},{"key":"2025120600444686000_13.5.e068310.14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5694\/mja16.00066","article-title":"Using opioids in general practice for chronic non\u2010cancer pain: an overview of current evidence","volume":"204","author":"Currow","year":"2016","journal-title":"Med J Aust"},{"key":"2025120600444686000_13.5.e068310.15","doi-asserted-by":"crossref","DOI":"10.5694\/mja15.00174","article-title":"Safety of opioid patch initiation in Australian residential aged care","volume":"203","author":"Gadzhanova","year":"2015","journal-title":"Med J Aust"},{"key":"2025120600444686000_13.5.e068310.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0115-7"},{"key":"2025120600444686000_13.5.e068310.17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bcp.13026","article-title":"Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated","volume":"82","author":"Gisev","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025120600444686000_13.5.e068310.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"2025120600444686000_13.5.e068310.19","unstructured":"Australian Bureau of Statistics . Census of population and housing: TableBuilder Pro. Australia, 2016. Available: https:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/PrimaryMainFeatures\/2073.0?"},{"key":"2025120600444686000_13.5.e068310.20","unstructured":"Australian Bureau of statistics . 3101.0-Australian demographic statistics. 2018. Available: https:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/3101.0Main+Features1Jun%202018?OpenDocument="},{"key":"2025120600444686000_13.5.e068310.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"2025120600444686000_13.5.e068310.22","unstructured":"Department of Health and Ageing . Trends in and drivers of Pharmaceutical Benefits Scheme expenditure 2013. 2013. Available: http:\/\/www.pbs.gov.au\/statistics\/asm\/2010\/australian-statistics-on-medicine-2010.pdf [Accessed 26 Jan 2021]."},{"key":"2025120600444686000_13.5.e068310.23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/pds.4329","article-title":"To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?","volume":"27","author":"Gisev","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120600444686000_13.5.e068310.24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1071\/PY20270","article-title":"Patterns of real-world opioid prescribing in Australian general practice (2013-18)","volume":"27","author":"Busingye","year":"2021","journal-title":"Aust J Prim Health"},{"key":"2025120600444686000_13.5.e068310.25","unstructured":"World Health Organization Collaborating Centre for Drugs Statistics Methodology . ATC\/DDD index. 2021. Available: http:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"2025120600444686000_13.5.e068310.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025840","article-title":"Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol","volume":"8","author":"Gisev","year":"2018","journal-title":"BMJ Open"},{"key":"2025120600444686000_13.5.e068310.27","unstructured":"New South Wales Centre for Health Record Linkage . Quality assurance. St Leonards, NSW: NSW CHeReL. 2023. Available: https:\/\/www.cherel.org.au\/quality-assurance"},{"key":"2025120600444686000_13.5.e068310.28","unstructured":"Australian Bureau of Statistics . 1270.0.55.005-Australian Statistical Geography Standard (ASGS): Volume 5-Remoteness Structure, 2016. 2018. Available: https:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/1270.0.55.005Main+Features1July%202016?OpenDocument [Accessed 29 Jan 2021]."},{"key":"2025120600444686000_13.5.e068310.29","unstructured":"Pink B . Technical paper: Socio-Economic Indexes for Areas (SEIFA) 2011. Canberra, ACT: Commonwealth of Australia, 2013."},{"key":"2025120600444686000_13.5.e068310.30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3945"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-068310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:44:55Z","timestamp":1765010695000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-068310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,17]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-068310"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-068310","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}